<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951623</url>
  </required_header>
  <id_info>
    <org_study_id>2018-523-00CH1</org_study_id>
    <nct_id>NCT03951623</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients</brief_title>
  <official_title>The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523, a Syk Inhibitor in Adult Patients of Immune Thrombocytopenia: a Randomized, Double Blinded, Placebo Controlled Phase Ib Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult&#xD;
      patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximate 51 to 60 patients will be enrolled in dose escalation (3 cohorts, 8-20 subjects&#xD;
      each with the ratio of 3:1 vs Placebo) .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with any Adverse Event</measure>
    <time_frame>From first dose to within 28 days after the last dose</time_frame>
    <description>Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 15, 16, 29, 43 and 47</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in a selected time interval (AUC0-t)</measure>
    <time_frame>Day 15, 16, 29, 43 and 47</time_frame>
    <description>Area under the concentration-time curve in a selected time interval (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Clinical Remission</measure>
    <time_frame>Day 1 to 8 weeks treatment</time_frame>
    <description>Rate of Clinical Remission was defined as the proportion of patients with two consecutive visits in the first 8 weeks (including the 8th week) during the medication period, platelet count ≥30×10^9/L, and a 2-fold increase from baseline (no emergency treatment during the period)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Immune Thrombocytopenia (ITP)</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible subjects will be treated with planned dose of 100 mg, 200 mg and 300 mg HMPL-523 once daily for 8 weeks and 16 weeks open-label treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible subjects will be treated with HMPL-523 matching placebo once daily for 8 weeks and 16 weeks open-label treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-523</intervention_name>
    <description>HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.</description>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form&#xD;
&#xD;
          2. 18~75 years old male of female&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          4. Diagnosed immune thrombocytopenia before randomization with platelet decrease for more&#xD;
             than 6 months.&#xD;
&#xD;
          5. Patients with refractory or relapsed ITP who have been treated with 1st line anti-ITP&#xD;
             regimen or have experienced splenectomy.&#xD;
&#xD;
          6. Relative stable disease with World Health Organization (WHO) bleeding score of 0-1 and&#xD;
             no rescue treatment needed within 2 weeks based on investigator's judgment.&#xD;
&#xD;
          7. Laboratory tests meet the following conditions：&#xD;
&#xD;
               -  During screening stage, twice PLT&lt;30x10^9/L(exceed 24 hours)&#xD;
&#xD;
               -  Hb≥90g/L(if iron-deficiency anemia,Hb&gt;80g/L),WBC&gt;2.5x10^9/L, NEU&gt;1.8x10^9/L&#xD;
&#xD;
               -  Crea≤1.5xULN and CCR≥50mL/min&#xD;
&#xD;
               -  TBIL、ALT、AST≤1.5xULN&#xD;
&#xD;
               -  Amylase、lipase&lt;ULN&#xD;
&#xD;
               -  INR、APTT&lt;20%xULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with secondary thrombocytopenia or patients have other auto immune diseases&#xD;
             who need long term steroids or immunosuppressants treatment.&#xD;
&#xD;
          2. Patients with Myelofibrosis, Myelodysplastic syndrome, Aplastic anemia, or other&#xD;
             hematologic malignancies.&#xD;
&#xD;
          3. Have splenectomy within 12 weeks before randomization&#xD;
&#xD;
          4. Major surgery was performed within 4 weeks before randomization;Or require major&#xD;
             elective surgery during the study period.&#xD;
&#xD;
          5. Have malignant tumor(except basal cell carcinoma of skin and carcinoma in situ of&#xD;
             cervix)&#xD;
&#xD;
          6. Have previous/significant arterial/venous embolic disease&#xD;
&#xD;
          7. History of serious cardiovascular disease, or QTc≥450 ms.&#xD;
&#xD;
          8. Patients with resistant hypertension (Systolic blood pressure ≥140 mmHg or Diastolic&#xD;
             blood pressure ≥90 mmHg)&#xD;
&#xD;
          9. Has a history of severe gastrointestinal diseases, such as dysphagia, active gastric&#xD;
             ulcer, and is unable to take oral medication or has absorption disorder&#xD;
&#xD;
         10. HIV infection&#xD;
&#xD;
         11. Uncontrolled, active infections&#xD;
&#xD;
         12. Known history of clinically significant liver disease, such as hepatitis b（HBV DNA&#xD;
             ≥2000IU/mL (or ≥1×104 copies)）, hepatitis c, or cirrhosis&#xD;
&#xD;
         13. Prior anti-ITP emergency treatment within 2 weeks before randomization.&#xD;
&#xD;
         14. Prior anti-ITP treatment within 4 weeks before randomization except for stable dose&#xD;
             steroids, including but not limited to Thrombopoietin, thrombopoietin receptor&#xD;
             agonist, azathioprine, cyclosporine A and mycophenolate mofetil.&#xD;
&#xD;
         15. Any condition requiring anti-coagulant therapy or the regular use of any medication&#xD;
             having effluence to Platelet function.&#xD;
&#xD;
         16. Exposure to Rituximab 14 weeks prior to randomization.&#xD;
&#xD;
         17. Treament with Chinese medicine within 1 week before randomization.&#xD;
&#xD;
         18. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized&#xD;
             by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450&#xD;
             isoform 1A2, and are identified as narrow therapeutic drugs within 14 days or 5&#xD;
             half-lives, whichever is longer, prior to initiation of study treatment.&#xD;
&#xD;
         19. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)&#xD;
&#xD;
         20. Allergic to study drug active ingredient or excipient&#xD;
&#xD;
         21. Subjects who have participated in clinical studies of drugs or invasive medical&#xD;
             devices within 4 week before randomization&#xD;
&#xD;
         22. Subjects have severe psychological or mental abnormalities&#xD;
&#xD;
         23. Alcoholic or drug abuser&#xD;
&#xD;
         24. Female subjects during pregnancy and lactation&#xD;
&#xD;
         25. The investigator considered that the subjects were not suitable to participate in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyan Yin</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jiayi Mai</last_name>
    <phone>086-021-20673063</phone>
    <email>Jiayim@hmplglobal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood diseases hospital, Chinese academy of medical university</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renchi Yang</last_name>
      <email>rcyang65@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>syk inhibitor</keyword>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

